The aim of the GenMed project is to build the necessary IT infrastructure in Estonia to apply personalised medicine principles in clinical practice so that personalised medicine could benefit all people in Estonia. In the course of the project, solutions for pharmacogenetics and polygenic risk scores are introduced as part of the national e-health system. This results in suggestions in prescriptions about drug dosage, as well as indicating the inherited risk of diabetes and heart disease based on the patient’s DNA.
The algorithm of pharmacogenetic recommendations is based on the research of the University of Tartu, which was selected by the International Personnel Medicine Consortium (ICPerMed) as the best personalised medicine practice in 2019. The algorithm analyzes the patient’s gene data, and if the patient has any medication for which the amount of the drug should be changed, it informs the doctor. | |
Polygenic risk scores analyse a person’s thousands of genetic traits and assess a person’s inherited risk of developing chronic diseases. The GenMed project uses the risk scores for type 2 diabetes and cardiovascular diseases previously developed by the Institute of Genomics. |
From 2019 until 2022.
The IT solution of the project is coordinated and implemented by the Centre of Personalised Medicine and Health Informatics of the University of Tartu (Institute of Computer Science together with the Institute of Genomics). The development of the IT solution is led by Prof. Jaak Vilo with a team that includes top scientists and specialists in their field. Competencies have been developed in cooperation with the BIIT Bioinformatics research group of the University of Tartu and the data science company STACC. In addition, the Ministry of Social Affairs, the Institute for Health Development, the Estonian Health Insurance Fund and the Health and Welfare Information Systems Center participate in the project
Jaak Vilo Personaalmeditsiini ja terviseinformaatika keskus (room 2042) |